Profile data is unavailable for this security.
About the company
Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Its Specialized BioTherapeutics segment is developing and focused on the commercialization of HyBryte (a proposed name of SGX301), a novel photodynamic therapy (PDT), utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). Development programs in this segment also include expansion of synthetic hypericin (SGX302) into psoriasis and dusquetide (SGX942 and SGX945) for the treatment of inflammatory diseases. Its Public Health Solutions segment includes development programs for RiVax, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease and its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax, its vaccine candidate for the prevention of COVID-19.
- Revenue in USD (TTM)494.62k
- Net income in USD-7.04m
- Incorporated1987
- Employees13.00
- LocationSoligenix IncSUITE C-10, 29 EMMONS DRIVEPRINCETON 08540United StatesUSA
- Phone+1 (609) 538-8200
- Fax+1 (609) 452-6467
- Websitehttps://www.soligenix.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nascent Biotech Inc | 0.00 | -1.92m | 8.30m | -- | -- | -- | -- | -- | -0.012 | -0.012 | 0.00 | -0.003 | 0.00 | -- | -- | -- | -1,256.81 | -708.50 | -- | -- | -- | -- | -- | -589.83 | -- | -- | -- | -- | -- | -- | 25.47 | -- | -- | -- |
| Transcode Therapeutics Inc | 0.00 | -17.91m | 8.33m | 10.00 | -- | 2.65 | -- | -- | -75.48 | -75.48 | 0.00 | 0.182 | 0.00 | -- | -- | 0.00 | -334.48 | -133.14 | -973.00 | -181.26 | -- | -- | -- | -- | -- | -90.11 | 0.00 | -- | -- | -- | -5.59 | -- | -- | -- |
| Check Cap Ltd | 0.00 | -17.57m | 8.48m | 85.00 | -- | 0.3581 | -- | -- | -3.00 | -3.00 | 0.00 | 4.05 | 0.00 | -- | -- | -- | -49.87 | -54.23 | -53.46 | -60.24 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 8.06 | -- | -2.46 | -- |
| Calidi Biotherapeutics Inc | 0.00 | -24.92m | 8.73m | 41.00 | -- | -- | -- | -- | -5.41 | -5.41 | 0.00 | -1.82 | 0.00 | -- | -- | 0.00 | -279.89 | -- | -- | -- | -- | -- | -- | -- | -- | -27.58 | -- | -- | -100.00 | -- | -14.90 | -- | -- | -- |
| Traws Pharma Inc | 226.00k | -137.05m | 8.77m | 16.00 | -- | -- | -- | 38.80 | -138.17 | -138.17 | 0.2557 | 6.03 | 0.0092 | -- | 12.91 | 14,125.00 | -557.63 | -63.43 | -896.39 | -85.72 | -- | -- | -60,641.15 | -3,257.92 | -- | -- | 0.00 | -- | 0.00 | -28.72 | 0.0844 | -- | -- | -- |
| Inhibikase Therapeutics Inc | 79.57k | -18.38m | 8.88m | 8.00 | -- | 1.68 | -- | 111.63 | -2.93 | -2.93 | 0.0126 | 0.7063 | 0.0051 | -- | -- | 9,946.25 | -117.93 | -66.49 | -148.63 | -85.55 | -- | -- | -23,102.16 | -1,139.14 | -- | -- | 0.00 | -- | 111.03 | -42.21 | -5.40 | -- | -- | -- |
| Soligenix Inc | 494.62k | -7.04m | 9.21m | 13.00 | -- | 1.80 | -- | 18.63 | -9.58 | -9.58 | 0.6152 | 2.25 | 0.0418 | -- | 8.70 | 38,047.69 | -59.45 | -75.40 | -121.64 | -154.32 | 8.75 | 22.83 | -1,423.81 | -620.02 | -- | -- | 0.4421 | -- | -11.54 | -30.67 | 55.50 | -- | -- | -- |
| Viracta Therapeutics Inc | 0.00 | -45.34m | 9.27m | 40.00 | -- | -- | -- | -- | -1.16 | -1.16 | 0.00 | 0.0678 | 0.00 | -- | -- | 0.00 | -83.82 | -86.35 | -140.98 | -106.38 | -- | -- | -- | -11,853.94 | -- | -59.78 | 0.8753 | -- | -- | -- | -3.78 | -- | -- | -- |
| BioCardia Inc | 428.00k | -8.56m | 9.28m | 16.00 | -- | -- | -- | 21.68 | -5.40 | -5.40 | 0.2636 | -0.9233 | 0.0923 | -- | 6.85 | 26,750.00 | -184.48 | -107.34 | -1,075.25 | -154.17 | -- | -- | -1,999.77 | -1,779.24 | -- | -- | -- | -- | -64.72 | -5.26 | 2.82 | -- | -28.89 | -- |
| Galecto Inc | 0.00 | -25.43m | 9.35m | 13.00 | -- | 0.3445 | -- | -- | -23.45 | -23.45 | 0.00 | 21.74 | 0.00 | -- | -- | 0.00 | -59.06 | -48.46 | -75.34 | -52.36 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 37.77 | -- | -- | -- |
| Molecular Templates Inc | 25.47m | -15.63m | 9.36m | 62.00 | -- | 1.32 | -- | 0.3674 | -2.70 | -2.70 | 4.24 | 1.08 | 0.8189 | -- | 47.65 | 410,806.40 | -50.24 | -51.78 | -113.26 | -73.14 | -- | -- | -61.35 | -228.33 | -- | -- | 0.00 | -- | 190.10 | 33.96 | 91.24 | -- | -48.87 | -- |
| GlycoMimetics Inc | 10.00k | -39.11m | 9.85m | 35.00 | -- | 0.4911 | -- | 985.31 | -0.6071 | -0.6071 | 0.0002 | 0.3111 | 0.0002 | -- | 0.0685 | 285.71 | -90.71 | -43.60 | -103.87 | -47.82 | -- | -- | -391,132.40 | -2,243.52 | -- | -- | 0.00 | -- | -86.67 | -- | 20.97 | -- | -29.82 | -- |
| Curative Biotechnology Inc | 0.00 | -6.02m | 9.94m | 4.00 | -- | -- | -- | -- | -0.0105 | -0.0105 | 0.00 | -0.0018 | 0.00 | -- | -- | 0.00 | -339.98 | -- | -- | -- | -- | -- | -- | -- | -- | -5.51 | -- | -- | -- | -- | -302.92 | -- | -- | -- |
| Kiora Pharmaceuticals Inc | 16.02m | 2.67m | 10.22m | 12.00 | -- | 0.3087 | 3.79 | 0.6379 | -7.76 | -7.76 | 6.61 | 11.14 | 0.5279 | -- | 7.16 | 1,335,000.00 | 10.54 | -70.52 | 11.20 | -81.86 | -- | -- | 19.98 | -2,040.61 | -- | -- | 0.00 | -- | -- | -- | 3.97 | -- | -- | -- |
| Conduit Pharmaceuticals Inc | 0.00 | -5.17m | 10.22m | 7.00 | -- | -- | -- | -- | -0.0667 | -0.0667 | 0.00 | -0.0738 | 0.00 | -- | -- | 0.00 | -312.39 | -- | -- | -- | -- | -- | -- | -- | -- | -21.32 | -- | -- | -- | -- | 89.05 | -- | -- | -- |
Data as of Oct 07 2024. Currency figures normalised to Soligenix Inc's reporting currency: US Dollar USD
2.00%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Old National Bank (Investment Management)as of 30 Jun 2024 | 10.00k | 1.01% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 3.18k | 0.32% |
| Nomura Securities Co., Ltd. (Private Banking)as of 31 Mar 2024 | 1.88k | 0.19% |
| First Wilshire Securities Management, Inc.as of 31 Mar 2024 | 1.46k | 0.15% |
| Two Sigma Investments LPas of 31 Mar 2024 | 796.00 | 0.08% |
| HRT Financial LLCas of 31 Mar 2024 | 782.00 | 0.08% |
| Two Sigma Securities LLCas of 31 Mar 2024 | 715.00 | 0.07% |
| Tower Research Capital LLCas of 31 Mar 2024 | 435.00 | 0.04% |
| Plante Moran Financial Advisors LLCas of 31 Mar 2024 | 299.00 | 0.03% |
| Morgan Stanley & Co. LLCas of 31 Mar 2024 | 224.00 | 0.02% |
More ▼
Data from 31 Mar 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
